Residual Atherosclerotic Cardiovascular Disease Risk in Statin Users: A Systematic Review and Meta-Analysis.

J Am Heart AssocAug 20, 2026 (epub)
Clinical ResearchCardiology

Alexandre H Watanabe, Lori D Bash, Tracy Westley et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated residual atherosclerotic cardiovascular disease (ASCVD) risk among statin users, analyzing observational studies from January 2013 to August 2023. The overall residual composite risk was found to be 12.3 per 1000 person-years (PPY), with higher rates in individuals with prior ASCVD (15.8 PPY).

Key findings

  • Residual composite ASCVD risk in statin users was 12.3 PPY.
  • Adults with prior ASCVD had a higher risk of 15.8 PPY.
  • Myocardial infarction rate was 8.23 PPY in the overall population.
  • Cardiovascular-related death rate was estimated at 4.3 PPY.

Why it matters

Understanding residual ASCVD risk in statin users is crucial for clinicians to identify treatment gaps and optimize patient management strategies, potentially improving cardiovascular outcomes.

Source

PubMed · PMID 42622218

Published in J Am Heart Assoc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.